Loading stock data…
Aquestive Therapeutics, Inc. (AQST)
$3.68-0.09 (-2.39%)
Market ClosedLast close Jul 24
Aquestive Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aquestive Therapeutics, Inc. in the Healthcare sector is trading at $3.68 with a market capitalization of $462M. Wall Street consensus targets $8.89 (9 analysts), implying a +141.5% move over the next 12 months. The stock is currently near its 52-week low of $2.93, remaining 22.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +141.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.45M↑ | $13.02M↑ | $12.81M↑ | $10.00M↑ | $8.72M |
| Gross Profit | $10.98M↑ | $7.18M↓ | $8.30M↑ | $5.44M↑ | $5.07M |
| Operating Income | -$4.20M↑ | -$28.84M↓ | -$11.48M↓ | -$11.37M↑ | -$19.36M |
| Net Income | -$8.06M↑ | -$31.86M↓ | -$15.45M↓ | -$13.55M↑ | -$22.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of b...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$461.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
202.36%
Volume
Today's trading volume
2.86M
Recent News
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Does US manufacturing give drugmakers a speed edge?
Aquestive’s fast response to an FDA rejection reveals why some drugmakers are betting on domestic operations despite pricing pressures and overseas supply dependencies.
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) just kicked off its latest quarterly results with some...
Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Aquestive Therapeutics Inc (AQST) reports a 66% revenue increase and outlines strategic milestones, despite challenges in product launch timelines.